glaucoma
(5)
Vivid Vision
Vivid Vision is a San Francisco medical technology company that turns virtual reality headsets into tools for vision care. Founded in 2014 by programmer James Blaha, who built the first prototype to treat his own lazy eye, the company started with VR games for amblyopia and strabismus and now runs two lines: a clinical and at-home vision therapy suite used in clinics across 50+ countries, and Vivid Vision Perimetry (VVP), a VR-based visual field test being adopted as a digital endpoint in pharmaceutical clinical trials for glaucoma, AMD, and geographic atrophy.
Myra Vision
Myra Vision is a Campbell, California medical device company developing the Calibreye Titratable Glaucoma Therapy Surgical System - a next-generation aqueous shunt with adjustable outflow channels that let surgeons fine-tune intraocular pressure in glaucoma patients non-invasively in the clinic, long after the implant goes in.
Avisi Technologies
Avisi Technologies is a clinical-stage ophthalmic medical device company building VisiPlate, an ultrathin, nanotechnology-enabled aqueous shunt that drains excess fluid from the eye to lower pressure in glaucoma patients. Spun out of the University of Pennsylvania's Y-Prize program in 2017, the company is advancing VisiPlate through the FDA-cleared SAPPHIRE pivotal trial and has raised roughly $21.7M to date, including a $10.7M Series A in February 2026.
QURA, Inc.
QURA, Inc. is a preclinical medical-technology company in Massachusetts building a tiny implanted sensor that continuously measures blood pressure and wirelessly transmits medical-grade waveform data to patients and physicians in real time. Its QSmart platform - a vitamin-sized QSense implant paired with software and analytics - aims to replace the occasional cuff reading with always-on monitoring, targeting hypertension, the leading cardiovascular risk factor worldwide. The technology grew out of an earlier wireless implantable pressure sensor developed for glaucoma (intraocular pressure) monitoring.
ViaLase, Inc.
ViaLase, Inc. is a clinical-stage medical technology company in Aliso Viejo, California building the first femtosecond laser designed to treat primary open-angle glaucoma without cutting into the eye. Its ViaLuxe Laser System pairs micron-level, high-definition imaging with a femtosecond laser to perform a noninvasive, image-guided trabeculotomy - branded FLigHT - that creates a drainage channel through the trabecular meshwork to lower intraocular pressure. Founded in 2019 by femtosecond-laser pioneer Tibor Juhasz, the company has raised more than $115 million, earned a CE Mark in Europe, and begun a U.S. IDE clinical trial.